Back to Stakeholders
Categories

2 domains / 4 areas / 2 specializations

Care Delivery & Psychedelic Facilitation
Care Delivery & Psychedelic Facilitation
Psychedelic Healthcare ImplementationHealth Economists
Government, Policy & Advocacy
Government, Policy & Advocacy
Public Sector Health & Drug GovernanceHealth Technology Assessment Agencies

Canadian Drug Agency (CDA-AMC)

Canadian public HTA and reimbursement review body supporting evidence appraisal for access decisions.

Reimbursement & Market Access Snapshot

Health Economists

Service Model

HTA / Value Assessment Body

Jurisdiction

National

Coverage

1 country

Last Verified

Apr 8, 2026

Focus Areas

HTA Evidence AppraisalCost-Effectiveness ModelingCoverage Policy DesignFormulary & Access Criteria

Evidence Requirements

Clinical Efficacy EndpointsComparative EffectivenessCost-EffectivenessBudget ImpactReal-World Evidence

Market Access Notes

CDA-AMC recommendations and evidence appraisals support reimbursement decision-making across Canadian public drug plans, including esketamine evaluations.

Verification

Verified

Psychedelic Focus

Psychedelic-Adjacent Focus

Engagement Status

Active

Primary Access Link

Source Evidence

CDA-AMC - Esketamine (Spravato)

https://www.cda-amc.ca/esketamine-spravato

CADTH CDEC Final Recommendation - Esketamine (Spravato)

https://www.cadth.ca/sites/default/files/cdr/complete/SR0621%20Spravato%20-%20CDEC%20Final%20Recommendation%20May%2028%2C%202020_for%20posting.pdf

Quick Facts

Website
Visit